Ocular Therapeutix Inc (NASDAQ: OCUL) on Friday, soared 6.62% from the previous trading day, before settling in for the closing price of $8.46. Within the past 52 weeks, OCUL’s price has moved between $4.79 and $11.77.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 72.05% over the last five years. The company achieved an average annual earnings per share of -17.19%. With a float of $133.72 million, this company’s outstanding shares have now reached $159.26 million.
The firm has a total of 274 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.66%, operating margin of -342.52%, and the pretax margin is -323.44%.
Ocular Therapeutix Inc (OCUL) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ocular Therapeutix Inc is 16.05%, while institutional ownership is 74.31%. The most recent insider transaction that took place on Jun 02 ’25, was worth 111,581. In this transaction Chief Medical Officer of this company sold 13,861 shares at a rate of $8.05, taking the stock ownership to the 206,805 shares. Before that another transaction happened on Jun 02 ’25, when Company’s Officer proposed sale 13,861 for $8.05, making the entire transaction worth $111,524.
Ocular Therapeutix Inc (OCUL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -17.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.61% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Ocular Therapeutix Inc (OCUL) is currently performing well based on its current performance indicators. A quick ratio of 10.14 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Analysing the last 5-days average volume posted by the [Ocular Therapeutix Inc, OCUL], we can find that recorded value of 2.03 million was better than the volume posted last year of 1.48 million. As of the previous 9 days, the stock’s Stochastic %D was 91.95%. Additionally, its Average True Range was 0.52.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 99.39%, which indicates a significant increase from 99.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.87% in the past 14 days, which was lower than the 78.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.51, while its 200-day Moving Average is $8.46. Now, the first resistance to watch is $9.21. This is followed by the second major resistance level at $9.39. The third major resistance level sits at $9.75. If the price goes on to break the first support level at $8.67, it is likely to go to the next support level at $8.31. Now, if the price goes above the second support level, the third support stands at $8.13.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
Market capitalization of the company is 1.44 billion based on 159,300K outstanding shares. Right now, sales total 63,720 K and income totals -193,510 K. The company made 10,700 K in profit during its latest quarter, and -64,050 K in sales during its previous quarter.
